<DOC>
	<DOC>NCT00387634</DOC>
	<brief_summary>evaluate safety and immunogenicity of first TBE booster and long-term immunogenicity up to 5 years after first TBE booster</brief_summary>
	<brief_title>Safety and Long-term Evaluation (up to 5 Years) of First Booster Immunization With Novartis' TBE Vaccine for Adults in Adolescents and Adults</brief_title>
	<detailed_description />
	<mesh_term>Encephalitis</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>healthy subjects who have completed study V48P7 acute illness at day of immunization general decrease in resistance progressive neurological disorders history of febrile or afebrile convulsions major congenital defects serious chronic illness hypersensitivity to study vaccine treatment with immunosuppressants or systemic corticosteroids, immunoglobulins, whole blood or plasma derivates</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>68 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>tick born encephalitis, TBE, adults</keyword>
</DOC>